UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF OHIO EASTERN DIVISION

IN RE: DAVOL, INC./C.R. BARD, INC., POLYPROPYLENE HERNIA MESH PRODUCTS LIABILITY LITIGATION

Case No. 2:18-md-2846

JUDGE EDMUND A. SARGUS, JR. Magistrate Judge Kimberly A. Jolson

This document relates to: Johns v. CR Bard et al, Case No. 2:18-cv-01509

MOTIONS IN LIMINE ORDER NO. 2

September 3, 2020 Conference on Motions in Limine

This matter came before the Court for a status conference on September 3, 2020. Upon consideration of the parties' briefs and their arguments presented, the Court in accordance with the conclusions made on the record at the hearing held as follows:

Plaintiff's Motion *in Limine* No. 15 to Exclude Evidence and Arguments Relating to the Hospital's Surgical Consent Forms (ECF No. 232) is **DENIED**.

Defendants' Motion in Limine No. 2 to Exclude Evidence and Arguments Concerning Material Safety Data Sheets (ECF No. 175) is **DENIED IN PART**. The parties may present evidence related to Material Safety Data Sheets ("MSDS"), but the Court will provide an instruction to the jury regarding the legal significance of MSDS and will issue a written decision on this motion.

The Court reserved ruling on and ordered supplemental briefing regarding Plaintiff's Motion *in Limine* No. 2 to Exclude Reference to Reason for Addition of Medical Application Statement to Marlex Material Safety Data Sheet (ECF No. 234). The Court ordered Bard to file supplemental briefing by Wednesday, September 9, 2020 regarding the relevant time frame when

Bard knew or had reason to believe the medical application statement was added to the MSDS for reasons other than safety concerns, and for Plaintiff to respond by Monday, September 14, 2020. The Court will issue a written decision on this motion.

Defendants' Motion *in Limine* No. 9 to Exclude Evidence and Argument Concerning "Medical Grade" Polypropylene (ECF No. 210) is **DENIED**.

Plaintiff's Motion in Limine No. 14 to Exclude Evidence of The ISO Standards/
Guidelines to Support Legal Theories or Establish the Product's Safety and Efficacy (ECF No. 230) is **DENIED IN PART.** The parties may present evidence of industry standards as relevant to and possibly evidence of the standard of care, but the Court will provide an instruction to the jury and will issue a written decision on this motion.

Defendants' Motion *in Limine* No. 3 to Exclude Reference to Irrelevant Bard devices (ECF No. 176) is **GRANTED IN PART**. The Court ordered Plaintiff to file supplemental briefing by Wednesday, September 9, 2020 regarding the admissibility of this evidence under Federal Rule of Evidence 404(b)(2), and for Bard to respond by Monday, September 14, 2020.

Defendants' Motion *in Limine* No. 1 to Preclude Any Evidence or Argument Concerning the Composix Kugel Ring Breaks and Recall (ECF No. 174) is **GRANTED IN PART**. The Court ordered Plaintiff to file supplemental briefing by Wednesday, September 9, 2020 regarding the admissibility of this evidence under Federal Rule of Evidence 404(b)(2), and the admissibility of the New York Times article under the hearsay rules, and for Bard to respond by Monday, September 14, 2020.

Defendants' Motion *in Limine* No. 4 to Exclude Any Evidence or Argument Concerning Alleged Complications and Defects that Did Not Occur in this Case (ECF No. 177) is **GRANTED**.

Plaintiff's Motion in Limine No. 3 to Exclude Evidence Relating to the United States

Food and Drug Administration (ECF No. 231) and Defendants' Motion in Limine No. 8 to

Exclude Evidence and Argument Concerning Alleged Fraud on the FDA, Misbranding, or

Violation of FDA Regulations (ECF No. 209) are **DENIED IN PART**. The parties may present

certain evidence related to information submitted or omitted in the course of the 510(k) clearance

of Bard's Ventralight ST, but the Court will provide an instruction to the jury regarding the

statutory and regulatory requirements for the 510(k) process and will issue a written decision on

this motion.

Plaintiff's Motion in Limine No. 16 to Exclude the FDA's Hernia Surgical Mesh Implants

Webpage (ECF No. 233) is **DENIED**.

The Court reserved ruling and will issue separate decisions on Plaintiff's Motion in

Limine No. 9 to Exclude Any Evidence or Argument that Ventralight ST or other "ST" Products

Are Still on the Market (ECF No. 245) and Defendants' Motion in Limine No. 5 to Preclude

Records, Testimony, Reference, Or Argument Concerning FDA Inspections And Third-Party

Audits (ECF No. 178).

IT IS SO ORDERED.

9=11=7070

DATE

EDMUND A. SARGUS, JR.

UNITED STATES DISTRICT JUDGE

3